CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
This Quarter Return
+16.35%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$995M
AUM Growth
+$995M
(-9.4%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-10.32%
Top 10 Holdings %
Top 10 Hldgs %
79.85%
Holding
33
New
6
Increased
13
Reduced
8
Closed
5
Top Buys
| 1 |
INSY
Insys Therapeutics, Inc.
INSY
|
$58.4M |
| 2 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$36.2M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$26.6M |
| 4 |
Pacific Biosciences
PACB
|
$19.6M |
| 5 |
Celldex Therapeutics
CLDX
|
$19M |
Top Sells
| 1 |
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
|
$87.3M |
| 2 |
United Therapeutics
UTHR
|
$56.5M |
| 3 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
$48M |
| 4 |
Supernus Pharmaceuticals
SUPN
|
$43.1M |
| 5 |
PTX
Pernix Therapeutics Holdings, Inc.
PTX
|
$34.9M |
Sector Composition
| 1 | Healthcare | 83.48% |
| 2 | Technology | 0.16% |
| 3 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Travere Therapeutics
TVTX
$1.56B
| $113M | 11.33% | 3,400,323 +292,613 | +9% | +$9.7M |
|
|
INSY
2
DELISTED
Insys Therapeutics, Inc.
INSY
| $107M | 10.77% | 2,984,094 +1,624,847 | +120% | +$58.4M |
|
|
EGRX
3
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $95.7M | 9.61% | 1,183,406 +447,484 | +61% | +$36.2M |
|
4
AbbVie
ABBV
$372B
| $87.3M | 8.77% | 1,298,900 +121,000 | +10% | +$8.13M |
|
|
AKRX
5
DELISTED
Akorn, Inc.
AKRX
| $80.5M | 8.09% | 1,843,756 -94,729 | -5% | -$4.14M |
|
|
6
United Therapeutics
UTHR
$13.8B
| $67.4M | 6.77% | 387,186 -325,000 | -46% | -$56.5M |
|
7
ANI Pharmaceuticals
ANIP
$2.03B
| $65.5M | 6.58% | 1,055,791 -68,876 | -6% | -$4.27M |
|
|
CSII
8
DELISTED
Cardiovascular Systems, Inc.
CSII
| $65.5M | 6.58% | 2,476,287 +283,787 | +13% | +$7.51M |
|
9
Orthofix Medical
OFIX
$592M
| $57.2M | 5.74% | 1,725,697 +145,479 | +9% | +$4.82M |
|
10
Enanta Pharmaceuticals
ENTA
$180M
| $55.8M | 5.61% | 1,241,321 -311,641 | -20% | -$14M |
|
|
11
Pacific Biosciences
PACB
$393M
| $31.1M | 3.12% | 5,398,861 +3,395,890 | +170% | +$19.6M |
|
|
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
| $26.6M | 2.68% | +303,131 | New | +$26.6M |
|
|
OSIR
13
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| $22.9M | 2.3% | 1,176,195 -22,141 | -2% | -$431K |
|
14
Catalyst Pharmaceutical
CPRX
$2.52B
| $22.8M | 2.29% | 5,517,885 +668,015 | +14% | +$2.76M |
|
|
15
Celldex Therapeutics
CLDX
$1.47B
| $19M | 1.9% | +751,748 | New | +$19M |
|
|
EPRS
16
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $12.9M | 1.3% | 2,265,988 +742,215 | +49% | +$4.24M |
|
|
DSCI
17
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $12.6M | 1.27% | 1,760,649 +128,022 | +8% | +$917K |
|
|
TVTY
18
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $12.1M | 1.22% | 1,010,025 -706,282 | -41% | -$8.46M |
|
19
ADMA Biologics
ADMA
$4.12B
| $9.58M | 0.96% | 1,034,721 +48,214 | +5% | +$446K |
|
20
Vericel Corp
VCEL
$1.83B
| $8.4M | 0.84% | 2,352,940 | – | – |
|
|
NSTG
21
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.93M | 0.7% | +449,325 | New | +$6.93M |
|
|
MSLI
22
DELISTED
Merus Labs International Inc.
MSLI
| $3.83M | 0.38% | 1,641,588 +272,974 | +20% | +$636K |
|
|
SIEN
23
DELISTED
Sientra, Inc.
SIEN
| $3.33M | 0.34% | +132,135 | New | +$3.33M |
|
24
Veracyte
VCYT
$2.39B
| $3.33M | 0.33% | 298,966 +63,106 | +27% | +$703K |
|
25
Lineage Cell Therapeutics
LCTX
$267M
| $2.38M | 0.24% | 655,540 -947,010 | -59% | -$3.44M |
|